Prestige Biopharma Files Patent for Novel Subcutaneous Antibody Delivery Platform IDC224
核心洞察
Prestige Biopharma IDC (搜索) has filed a patent for IDC224 (搜索), a next-generation subcutaneous delivery platform designed to enhance both administration convenience and therapeutic efficacy of antibody therapeutics.
The platform features a unique liquid-to-gel transition mechanism that facilitates sustained drug release, extends therapeutic duration, and reduces dosing frequency while enabling high-concentration antibody loading.
Pre-clinical studies demonstrated improved therapeutic efficacy compared to conventional methods in gastric, ovarian, and breast cancer models.
Prestige Biopharma IDC (搜索), the innovative drug research institute of Prestige Biopharma (搜索), announced on April 23, 2026, that it has filed a patent for IDC224 (搜索), a next-generation subcutaneous delivery platform designed to simultaneously enhance the administration convenience and therapeutic efficacy of antibody therapeutics. The development addresses significant technical barriers in converting intravenous antibody formulations to more patient-friendly subcutaneous alternatives.
Addressing Industry Shift to Subcutaneous Delivery
The global pharmaceutical and biotechnology industry is witnessing a strategic shift from intravenous to subcutaneous delivery methods, driven by high patient convenience and mitigation of risks associated with repeated vascular access. While most current antibody therapeutics are administered via intravenous infusion—typically requiring more than an hour and dedicated medical assistance—subcutaneous administration offers a rapid, highly convenient alternative for patients.
However, antibody therapeutics face significant technical barriers regarding the stable delivery of high-concentration formulations, necessitating advanced engineering for successful subcutaneous conversion. Prestige Biopharma IDC (搜索) has addressed these challenges with the development of its proprietary IDC224 (搜索) technology.
Innovative Liquid-to-Gel Technology
The IDC224 (搜索) platform is characterized by a unique liquid-to-gel transition mechanism where the drug is administered in a liquid state and subsequently transforms into a gel upon exposure to body temperature. This process facilitates the sustained release of the drug, effectively extending its therapeutic duration and reducing dosing frequency.
The platform enables the uniform loading of high-concentration antibodies, thereby maximizing delivery efficiency. It also secures a strong competitive edge in safety by utilizing biocompatible and biodegradable materials.
Pre-Clinical Validation
The project lead overseeing the development of IDC224 (搜索) stated, "This platform was engineered to optimize the mode of administration, drug delivery efficiency, and patient convenience in tandem. In pre-clinical studies applying this platform to gastric, ovarian, and breast cancer models, we confirmed improved therapeutic efficacy compared to conventional methods."
The representative added, "This patent is a follow-up to our existing composition patent and holds significant value as a 'use patent,' which newly defines the anticancer efficacy achieved through this specific composition."
Strategic Application to Tuznue®
The technology is designed to facilitate the potential subcutaneous conversion of Tuznue®, Prestige Biopharma (搜索)'s trastuzumab biosimilar, which is currently approved in Europe in its existing formulation. Tuznue® is a biosimilar of Herceptin® (trastuzumab) indicated for the treatment of patients with HER2 (搜索)-positive metastatic breast cancer, HER2-positive early breast cancer, and HER2-positive metastatic gastric cancer.
This technology holds substantial strategic value in further strengthening product competitiveness and enabling future differentiated administration options for patients and healthcare providers.
Future Applications
A spokesperson for Prestige Biopharma IDC (搜索) remarked, "The IDC224 (搜索) platform is designed not only to enhance the durability of an antibody's therapeutic effect but also to improve ease of administration. We plan to expand the application of this technology to a diverse portfolio of antibody therapeutics in the future."
Established in 2015 in Singapore, Prestige Biopharma (搜索) is a biopharmaceutical company with a diversified portfolio that includes a first-in-class antibody drug and key biosimilars referencing blockbuster drugs currently in clinical development.